Familial clustering and genome-wide linkage scans strongly support a genetic susceptibility to familial IgA nephropathy (IgAN), but genetic factors that predispose to sporadic IgAN are unknown. A high-throughput single nucleotide polymorphism (SNP) association study was conducted using a customized Illumina BeadChip in 732 white patients with biopsy-proven IgAN and 503 control subjects from Canada, France, and Finland. Approximately 93% of 1536 SNPs on the array were tag SNPs from Phase IϩII of the HapMap with a minor allele frequency Ն5%, designed to capture the common variants of genes within the critical interval of IGAN1 on chromosome 6q22 and 69 biologic candidate genes for IgAN. SNPs of suggestive or significant association were identified by using logistic regression to adjust for age, gender, study site, and population stratification. Despite using a dense marker set that covered an average interval of 6.5 kb between SNPs, there was no strong and consistent association signal within the IGAN1 critical interval. Among the biologic candidate genes examined, two significant association signals were found at IL5RA and TNFRSF6B, the latter being particularly interesting because this gene encodes a decoy receptor for a TNF family ligand that causes IgAN in mice when overexpressed. Pending replication, these data suggest that variants of IL5RA and TNFRSF6B may predispose to sporadic IgAN.
documented in donor kidneys with IgAN within weeks after they were inadvertently transplanted into recipients with other renal diseases. 8 Although IgAN is currently thought to be a systemic disorder of mucosal immunity, its pathobiology remains largely unknown. Presently, nonspecific measures, such as blood pressure control with an angiotensin converting enzyme inhibitor/angiotensin receptor blocker and fish oil treatment, are recommended as therapeutic options to delay the progression of this disease. 1 Familial clustering of IgAN has been well documented. 9 -13 In a family study of patients with biopsy-proven IgAN, a recurrence risk () of approximately 16 (95% confidence interval [CI], 6 to 48) was noted in the first-degree relatives and 2.4 (95% CI, 0.7 to 7.9) in the second-degree relatives. 11, 12 Additionally, recent genome-wide linkage scans of familial IgAN have identified significant or suggestive susceptibility loci on chromosomes 6q22 (IGAN1), 13 2q36, 14 4q26 -31, and 17q12-22. 15 Taken together, these data suggest a genetic predisposition to familial IgAN, although none of the susceptibility genes has been identified to date. In this paper, we report the results of our allelic association study in three cohorts of white patients with biopsy-proven IgAN from Canada, France, and Finland using a custom Illumina (San Diego, CA) BeadChip designed to comprehensively capture the common variants of all of the genes within the critical interval of IGAN1 and 69 biologic candidate genes for IgAN (Tables 1 and S1 ). Table 1 . List of candidate locus/genes examined in the study
Name of Candidate
Locus/Gene SNP ID in Table S1 Name of Candidate Locus/Gene SNP ID in Table S1 IGAN1 IL13  1510-1514  TNFRSF14 (HVEM)  1237-1238  IL13RA1  1515-1517  TNFRSF6B (DcR3)  1239-1241  IL13RA2  1518-1523  TNFSF13 (APRIL)  1242-1245  NOD2  1524-1526  TNFRSF13C (BAFF-R)  1246-1247  IL10  1527-1532  TNFRSF17 (BCMA)  1248-1252  TBET  1533-1536  TNFRSF13B (TACI) 1253-1261
All SNP ID and sequence information was derived from NCBI Build 36. Table S1 has details of the SNPs chosen for the specific candidate locus/gene.
RESULTS

Genotype and Phenotype Data
Of the 1536 single nucleotide polymorphisms (SNPs) attempted on our customized Illumina chip, 19 SNPs with low design scores generated either no genotypes or had more than 30% of the genotypes missing and were therefore excluded. Except for these SNPs, the genotype data (based on 1477 autosomal and 40 X chromosome SNPs that were successfully genotyped) were 99.0% complete. Eighteen autosomal and one X chromosome SNPs were monomorphic in the pooled controls. Overall, 94.5% of the polymorphic SNPs that were successfully genotyped had a minor allele frequency more than or equal to 5%. Seven subjects with discrepancies between the reported and genotyped sex were excluded from the analysis. Based on three duplicate samples (ϳ8500 genotypes), the genotype agreement was 99.8%. We also re-genotyped a randomly selected case and control samples from each site (n ϭ 200) for 6 tag SNPs (IGAN1: rs1342646, rs6569686, rs1203344; IL4R: rs1805015; IL5RA: rs340833; and TNFRSF6B: rs1291205) with suggestive/significant associations detected by logistic regression and found a concordant rate of genotype calls more than 98.8% for these SNPS between the GoldenGate (Illumina) and MassArray (Sequenom, San Diego, CA) assays. Thirty-eight (2.6%), 20 (1.4%), and 31 (2.1%) SNPs of the control subjects from Toronto, Finland, and France, respectively, deviated from Hardy-Weinberg Equilibrium (HWE, P Ͻ 0.001). The clinical characteristics of the study patients from each site are shown in Table 2 . Overall, the distributions of age and gender between cases and controls were similar for all three sites, but the French patients and controls tended to show more male predominance. In general, the Finnish patients were younger and had lower serum creatinine, proteinuria, and blood pressure at the time of their renal biopsy than the French and Canadian patients.
Analysis of Population Structure
Population stratification, defined as allele frequency differences between cases and controls resulting from systematic ancestry differences, can result in spurious false positive and false negative associations in genetic studies. 16 -18 We used EIGENSTRAT, a novel algorithm based on principal components analysis, to detect and correct for population structure in our study samples (Table S2) . 19 We tested the 10 top eigenvectors but identified that only the first two (PC1 and PC2) to be significantly associated with any within-site or between-site variation. Figure S1 shows a scatter plot of all of the samples from each site by the first two principal components (PC1 and PC2 Logistic Regression Analysis Table S3 shows the results of logistic regression analysis on the affection status (case versus control). With all sites combined, age and gender did not have any effect in this overall analysis. However, with Toronto as a reference site, Helsinki had an effect on the affection status (P ϭ 0.011), whereas St. Etienne did not. Additionally, both PC1 and PC2 also had a marginally significant effect (P ϳ 0.05 to 0.06). With each site considered individually, age had a marginal effect in the samples from St. Etienne (P ϭ 0.084) but not at the other sites. Gender did not have any effect at any site. PC1 had a significant effect for the Toronto samples (P ϭ 0.0023), whereas PC2 had a marginal effect for the Helsinki samples (P ϭ 0.087). These data are consistent with our analysis of population structure but further suggest that there were systematic differences in ancestry between the Toronto cases and controls, which is captured by PC1. Marginal systematic differences in ancestry were also suggested between the Helsinki cases and controls, which were captured by PC2. The latter finding may be related to a spurious sampling effect given the relatively small size of the control subjects. CLINICAL RESEARCH www.jasn.org
SNP Genotype Association Testing
To ensure adequate quality of our genotype data, we only analyzed SNPs with GenCall scores more than or equal to 0.7 and missing genotype proportion less than 0.3. For initial screening, we identified all SNPs with HWE P values more than 0.001 from control samples of each site and genotype association P value from the pooled sample or individual site sample less than 0.001. Using these criteria and the Cochrane-Armitage trend test, we identified a total of six SNPs with suggestive/ significant associations (Table 3) . We then repeated the association analysis using logistic regression to adjust for age, gender, study site, and the first two principal components from the EIGENSTRAT analysis. With this latter approach, we identified a total of nine SNPs with suggestive/significant associations (Table 4 ). In general, most of these associations were detected only in the French cohort by both the trend test and logistic regression, which showed similar results with minor changes of P values in either direction. However, three SNPs (rs6569686, rs1203344, rs1203350) in the Finnish cohort, which were insignificant by the trend test (P Ͼ 0.5; Table 3 ), became significant by logistic regression (P Յ 0.0001; Table 4 ). Of the 4 SNPs mapped to IGAN1, only one (rs1342646; P ϭ 0.0016, q value ϭ 0.28, Table 4 ) was mapped to a known gene (PTPRK; protein tyrosine phosphatase, receptor type, K). The remaining five SNPs were mapped to three biologic candidate genes: IL4R (rs1805015), IL5RA (rs340833), and TNFRSF6B (rs1291205, rs3208008, rs1291206), with the latter three at TNFRSF6B in tight linkage disequilibrium (pair-wise r 2 or DЈ all Ͼ0.98). Table 5 shows the HWE analysis in both controls and cases for these SNPs as well as their multivariate odds ratios. For rs1342646, the A-allele had a higher frequency in the French cases compared with controls (0.61 versus 0.50) and was associated with an increased homozygote (2.22; 95% CI, 1.27 to 3.86) odds ratio. For rs1805015, the G-allele had a lower frequency in the French cases compared with controls (0.096 versus 0.17) and was associated with low heterozygote (0.32) and homozygote (0.81) odds ratios, suggesting that this may be a protective allele at IL4R. However, the 95% CI for both of these odds ratios included 1, Therefore, these findings should be taken as suggestive evidence. For rs340833, the A-allele had a higher frequency in the French cases compared with controls (0.48 versus 0.43) and was associated with significant homozygote odds ratio (2.93; 95% CI, 1.75 to 4.90), suggesting that this may be a risk allele at IL5RA. Finally, the G-allele for rs1291205 had a lower frequency in the French cases compared with controls (0.16 versus 0.28) and was associated with significant heterozygote (0.34; 95% CI, 0.12 to 0.99) and homozygote odds ratio (0.17; 95% CI, 0.06 to 0.48), suggesting that this may be a protective allele at TNFRSF6B. These latter results, as expected due to strong linkage disequilibrium, are completely concordant between rs1291205, rs3208008, and rs1291206. The genotype counts for these SNPs with suggestive/significant associations are shown in Table 6 .
DISCUSSION
Familial clustering of cases and recent genome-wide linkage studies have strongly implicated a genetic predisposition to familial IgAN. 9 -15 However, the genetics of familial IgAN is complex as shown by recent reports of multiple significant/ suggestive loci on chromosomes 6q22 (IGAN1), 2q36, 4q26 -31, and 17q12-22. [12] [13] [14] [15] Nonetheless, IGAN1 appears to be a major locus that accounts for a large fraction of the families being studied in a genome-wide linkage scan. 13 Yet despite intense efforts, the identification of the disease gene for IGAN1 remains elusive. In this report, we present our findings on the largest case-control association study in IgAN conducted to date. Using high-throughput SNP genotyping, we provided a comprehensive scan for genotype association in the critical interval of IGAN1 as well as 69 biologic candidate genes with mostly tag SNPs with minor allele frequencies more than 0.05. We also applied EIGENSTRAT, a novel algorithm for genomic control, to detect and adjust for population structure. Our analysis on population structure within and between sites is instructive and revealed hidden ancestral differences between subgroups of the same ethnic group. Of note, we were unable to confirm a previous report of genetic association at the selectin gene cluster in Japanese patients. 22 Although racial difference may potentially explain this lack of replication, population stratification may also be a confounder in the previous study. Comparison of our results by the trend test and logistic regression with adjustment of covariates (including the population structure) further highlights the need for the latter approach for case-control association studies.
A key finding of our study is that, despite using a dense and a Multivariate odds ratio derived from logistic regression analysis, which is used to adjust for the effects of age, gender, study site, and the first two components (PC1 and PC2) from EIGENSTRAT analysis. X and O denote risk and wild-type alleles, respectively, for a specific SNP.
informative marker set (covering an average interval of 6.5 kb between SNPs) and a relatively large patient sample size, we failed to detect a strong and consistent association signal within the IGAN1 critical interval. Of the three tag SNPs with positive association we detected, only one (rs1342646) mapped to a known gene, but the other two could tag SNPs in other genes. In general, we do not expect the disease gene variant from IGAN1 to be associated with multiple tag SNPs. Thus, future study with even larger sample size will likely be required to identify the causative gene variant for IGAN1. There are several limitations of our study on the IGAN1 critical interval: 1) the HapMap focused only on SNPs with minor allele frequency more than 0.05, so we cannot exclude that rarer variation in the IGAN1 region are associated with sporadic disease; 2) although, on average, the HapMap captures most of the common variation across the genome, there may be sets of common variation that are absent from this database; 3) bins that had no tag SNPs that passed the Illumina bioinformatics prediction or that failed our quality control criteria are not well captured in this study. Nonetheless, based on our results, it appears that IGAN1 is unlikely to account for a large fraction of sporadic IgAN. Similar findings have been noted in common disorders, such as Alzheimer disease and breast cancer. We also found two significant association signals at IL5RA (rs340833; P ϭ 8.5 ϫ 10 Ϫ5 , q value ϭ 0.025) and TNFRSF6B (rs1291205; P ϭ 3.5 ϫ 10 Ϫ5 , q value ϭ 0.025). For rs340833, the A-allele was associated with significant homozygote odds ratio (2.93; 95% CI, 1.75 to 4.90), suggesting that this may be a risk allele at IL5RA. For rs1291205, the G-allele was associated with significant heterozygote (0.34; 95% CI, 0.12 to 0.99) and homozygote odds ratio (0.17; 95% CI, 0.06 to 0.48), suggesting that this may be a protective allele at TNFRSF6B. These latter results, as expected, are completely concordant between rs1291205, rs3208008, and rs1291206 because these SNPs are in tight linkage disequilibrium. Taken together, these findings suggest a genetic predisposition to sporadic IgAN. The fact that they were not replicated in our two other cohorts is not surprising because the sample size of these cohorts is too small to ensure proper power for replication. 23 Additional factors that may contribute to the lack of replication include locus and etiologic heterogeneity between different populations.
The biologic relevance of our candidate gene findings is not clear at this time. IL5RA encodes the alpha chain of the IL5 receptor, and signaling through this receptor may play a role in modulating Th1/Th2 polarity and immune regulation. 24 -26 By contrast, TNFRSF6B (or DcR3) encodes a decoy receptor for LIGHT (lymphotoxin-like, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor ex- pressed by T lymphocytes). [27] [28] [29] LIGHT is a TNF family ligand for lymphotoxin ␤ receptor (LT␤R), which mediates the proper expression of chemokines and adhesion molecules within intestinal lamina propria and determines the effective homing of IgA-producing plasma cell precursors. In additional, LT␤R is required for the development of mucosal lymphoid organs. Overexpression of LIGHT in transgenic mice results in an IgAN phenotype characterized by T cell-mediated intestinal inflammation, dysregulation of polymeric IgA production and clearance, mesangial IgA deposition, hematuria, and proteinuria. 30 TNFRSF6B (or DcR3), on the other hand, is a soluble receptor that competes with LT␤R for binding to LIGHT and may therefore serve as an antagonist to downregulate LIGHT-LT␤R signaling. 29 In conclusion, we have reported the largest allelic association study involving three cohorts of white patients, using high-throughput SNP genotyping to comprehensively survey the genes within the critical interval of IGAN1 and 69 biologic candidate genes for IgAN. Our study also represents the first association study in IgAN with control for population stratification. Our findings suggest that the causative gene variant for IGAN1 is not likely to account for a significant portion of sporadic IgAN. By contrast, we found significant association signals at IL5RA and TNFRSF6B, providing formal evidence for genetic susceptibility to sporadic IgAN. Pending replication by follow-up studies, our findings in this candidate locus/gene study may provide important insights into the pathobiology of sporadic IgAN. Furthermore, given their recent success in a number of common medical diseases, [31] [32] [33] [34] genome-wide association studies with a large patient sample size will also provide a promising approach to detect additional susceptibility genes for IgAN. The identification of molecular target(s) involved in disease initiation will provide the foundation for developing better diagnostic tests and mechanism-based therapeutic for this important disease.
CONCISE METHODS
Study Subjects
The study patients comprised of self-reported whites recruited from Toronto, Canada; St. Etienne, France; and Helsinki, Finland. All of them had biopsy-proven IgAN according to the pathologic criteria by World Health Organization. 8 We also reviewed their clinical records and excluded all patients with cirrhosis, systemic lupus erythematosus, gluten enteropathy, HIV infection, and Henoch-Schonlein purpura. 1 Ten patients were known to have familial IgAN and 9 patients were younger than 18 yr at the time of their renal biopsy. Age-and gender-matched local control subjects of European descent without any history of kidney disease were also recruited from each site. The Canadian control subjects were derived from a large family-based genetic study of autosomal dominant polycystic kidney disease (ADPKD) and comprised of spouses and unrelated family members without ADPKD, all with a normal urinalysis. The French control subjects were comprised of unrelated blood donors and healthy volunteers (medical staff and nurses). The Finnish control subjects were derived from a large family-based genetic study of ADPKD and comprised of spouses and unrelated family members without ADPKD, as well as a random sample of unrelated volunteers from the general population. All of the study subjects gave informed consent before their blood sampling for DNA extraction. All of the study patients also gave permission to review their clinical records. The Institutional Human Subject Review Board from each site approved the research protocol used in this study.
Design of Customized Illumina BeadChip
Taking advantage of the high-throughput genotyping technology and the invaluable resource provided by the HapMap project, 35 we designed a customized chip containing 1536 SNPs for candidate gene study using the BeadArray platform (Illumina). Candidate genes were selected based on their involvement in the known pathophysiology of IgAN. We considered biologic evidence, including gene function, prior genetic association or linkage studies, and animal models of IgAN. Because IGAN1 has been implicated as a major susceptibility locus for familial IgAN, 13 we devoted a significant portion of our SNPs to comprehensively survey its critical interval. We first downloaded all of the available SNPs from the HapMap Phase II database for the CEU samples (Release 21) within the "lod-1 support interval" (125,436,000 to 131,772,000: Hg18 build) of IGAN1 and organized them into linkage disequilibrium bins with pair-wise r 2 more than 0.8. From each bin, we then selected a tag SNP with the following characteristics: 1) minor allele frequency of 5% or more in the CEU, and 2) high design scores (Ͼ0.7) based on Illumina's in-house Bioinformatics predictive algorithms. Each tag SNP serves as a proxy that captures the common variants within a specific bin. In total, 962 tag SNPs from IGAN1 "lod-1 support interval" were placed in our custom chip, providing an average density of one tag SNP/6.5 kb. Using the same algorithm, we selected SNPs for other biologic candidate genes from the Phase IϩII HapMap database whenever possible, and from the SeattleSNPs and dbSNP databases in addition. A total of 69 biologic candidate genes (Tables 1 and S1 ) were also included in our customized arrays, including megsin, 1 Fc␣ receptor (CD89), 36 transferrin receptor, 37 selectin gene cluster, 22 Toll-like receptors, 24 and genes involved in Th1/Th2/Th17 immune response, 24 -26,38 LIGHT and BAFF signaling pathways. 30,39 -41 
DNA Isolation and Genotyping
Genomic DNA was extracted from peripheral blood using standard methods. DNA quantification was performed using the picogreen method to provide sample concentration of 50 ng/l in a 96-well plate format. High-throughput genotyping was performed on a customized Illumina BeadChip using with the GoldenGate assay according to the manufacturer's recommendation (http://icom.illumina.com/ General/pdf/LinkageIV/GOLDENGATE_ASSAY_FINAL.pdf), at the Center for Applied Genomics, Toronto. Genotype calls and GenCall scores were obtained for all of the SNPs on all thirteen 96-well plates simultaneously. Quality control measures included assessment of discordance between reported and genotyped gender using X-chromosome markers as well as concordance of genotypes between duplicate samples to which the genotyping group were blinded. To provide an independent validation of the genotypes of selected SNPs with suggestive/significant associations, we re-genotyped a randomly selected case and control samples from each site using the iPLEX MassARRAY assay (Sequenom; http://www.sequenom.com/seq_genotyping.html) at the Core Genotyping Centre of the University Health Network, Toronto.
Statistical Analysis
Detection and Correction for Population Structure.
To determine if there were different population structures between the cases and controls and across the samples from the three different sites, we used the "smartpca" program from the EIGENSTRAT package. 19 There are three steps to this analysis: First, principal components analysis is applied to genotype data to infer continuous axes of genetic variation. The axes of variation allow for the reduction of data to a small number of dimensions, describing as much variability as possible; they are defined as the top eigenvectors of a covariance matrix between samples. In data sets with ancestry differences between samples, axes of variation often have a geographic interpretation. For example, an axis describing a northwest-southeast cline in Europe would have values that gradually range from positive for samples from northwest Europe, to near zero in central Europe, to negative in southeast Europe. Second, genotypes and phenotypes are continuously being adjusted by amounts attributable to ancestry along each axis, via computing residuals of linear regressions. Third, association statistics are computed using ancestry-adjusted genotypes and phenotypes. F st is the ratio of between-subpopulation variance to total variance and P values were derived from the summed statistics across the eigenvector comparisons.
Logistic Regression Analysis.
We performed logistic regression (SAS, version 9.1, SAS Institute, Cary, NC) to test whether any of the following variables: age, gender, study site, and the first two principal components (PC1 and PC2) identified from the EIGENSTRAT algorithm, is associated with affection status (case or control). Similarly, we performed logistic regression to test whether age, gender, and the first two principal components (PC1 and PC2) influence the affection status within each site.
SNP Genotype Association Testing.
As an initial screen, we used Cochrane-Armitage trend test to detect genotype association. The primary analysis was a multivariate logistic regression model to test for association between individual SNPs and the affection status after adjusting for age, gender, site, and the first two principal components. An additive genetic model was assumed. For this analysis, age and gender were forced in the regression model, even though they were NS covariates. For SNPs with suggestive/significant associations, multivariate odds ratios were calculated for both heterozygotes and homozygotes. To address the inherent problem of multiple hypotheses testing, we adopted the False Discovery Rate (FDR) framework and applied the q value method. 42 The q value is a measure of statistical significance in terms of FDR, and a test with q value of 0.5 means that the expected FDR is 0.5 if we declare that test and all other tests with smaller q values significant.
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